[ad_1] Now in press & online @ Ophthalmology, the journal of the American Academy of Ophthalmology, the first phase 3 trial to evaluate suprachoroidal injection for treatment of an ocular disease… https://t.co/hgCc9WHHdu [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] Disruption brings harmony in biotech: The rise of anti-VEGF therapy shows what industry, academia, private practice can create together. https://t.co/WwBCk4kkr8 [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
RT @OphthalmicPro: Are you curious about gene therapy? Check out Dr. Thomas Ciulla’s article at https://t.co/82jHtEhRGq #ophthalmology #eye…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] RT @RetinalPhys: Clearside Biomedical said it has done significant preclinical testing of the anti-VEGF axitinib and plans to begin a clini… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] In San Francisco this week for the JP Morgan Healthcare Conference #jpm2020. Looking forward to connecting with old friends and colleagues. Please reach out if you want to catch up. [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
RT @OphthalmicPro: Gene therapy has gotten some major buzz in the medical community of late. In this issue, Dr. Thomas Ciulla gives us a pr…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] Vascular alterations in macular degeneration and diabetic retinopathy, reviewed in this chapter we just published…. https://t.co/X0OzpZAMga [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.